Kodiak Sciences Q2 EPS Forecast Lowered by Zacks Research

Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) - Research analysts at Zacks Research reduced their Q2 2025 earnings estimates for Kodiak Sciences in a report issued on Wednesday, June 4th. Zacks Research analyst R. Department now expects that the company will post earnings of ($1.02) per share for the quarter, down from their previous forecast of ($0.94). The consensus estimate for Kodiak Sciences' current full-year earnings is ($3.45) per share. Zacks Research also issued estimates for Kodiak Sciences' Q3 2025 earnings at ($0.99) EPS, Q4 2025 earnings at ($0.98) EPS, FY2025 earnings at ($4.08) EPS, Q1 2026 earnings at ($0.93) EPS, Q2 2026 earnings at ($0.94) EPS, Q3 2026 earnings at ($0.89) EPS, Q4 2026 earnings at ($0.88) EPS, FY2026 earnings at ($3.65) EPS, Q1 2027 earnings at ($0.76) EPS and FY2027 earnings at ($2.87) EPS.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.20).

Separately, HC Wainwright restated a "neutral" rating and set a $3.00 target price on shares of Kodiak Sciences in a report on Monday, March 31st.

Kodiak Sciences Stock Performance

KOD traded down $0.07 during trading on Friday, hitting $4.15. 240,745 shares of the stock were exchanged, compared to its average volume of 347,347. The firm has a 50 day simple moving average of $3.42 and a 200 day simple moving average of $5.36. The firm has a market cap of $218.97 million, a price-to-earnings ratio of -1.14 and a beta of 2.27. Kodiak Sciences has a 1 year low of $1.92 and a 1 year high of $11.60.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. PNC Financial Services Group Inc. increased its holdings in shares of Kodiak Sciences by 1,501.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,187 shares of the company's stock valued at $32,000 after acquiring an additional 2,988 shares during the period. American Century Companies Inc. increased its holdings in shares of Kodiak Sciences by 6.2% in the 4th quarter. American Century Companies Inc. now owns 59,967 shares of the company's stock valued at $597,000 after acquiring an additional 3,515 shares during the period. US Bancorp DE purchased a new position in Kodiak Sciences during the 4th quarter worth $40,000. Bank of New York Mellon Corp grew its stake in Kodiak Sciences by 5.3% during the 4th quarter. Bank of New York Mellon Corp now owns 98,102 shares of the company's stock worth $976,000 after buying an additional 4,927 shares during the last quarter. Finally, Deutsche Bank AG grew its stake in Kodiak Sciences by 8.9% during the 1st quarter. Deutsche Bank AG now owns 73,564 shares of the company's stock worth $207,000 after buying an additional 6,018 shares during the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Kodiak Sciences Company Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.